Just today, an early release in the finding of the immunotherapy drug nivolumab being use to treat non-Hodgkin's Lymphoma shows over 10% (4/29) of patients in complete remission. So I say that's pretty good. Dr. James Allison even said that for the 20-25% of patient that get an everlasting remission with Yervoy, that's great.

And those numbers will only go up.